Pharmaceutical Executive: September 2023

Click the title above for a link to open the Pharmaceutical Executive September 2023 issue in an interactive PDF format.

Lisa LeCointe-Cephas, SVP, chief ethics and compliance officer and office of general counsel, human health, Merck, uses her unique style of leadership—stop, drop, and roll—while elevating voices that need to be heard.

Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.

Early success ignites promise in reshaping standards of care for HER2 breast cancer.

Bacteria killer signals a milestone—and momentum—for microbiome therapeutics.

Injection buys valuable time to formulate care game plans in diabetes management.

Ushering in a novel class of drugs that attacks HIV at multiple stages of replication.

First-of-its-kind treatment offers hope in the fight against rare heart disease.

Integrating artificial intelligence and advanced analytics throughout operations offers pharma companies a pathway to offset impending drug patent expirations.

With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.

Strong economic data in other sectors mean rising ‘real’ rates.

The implications of Twitter’s rebrand for healthcare marketing.

Embrace the tools that solve real problems and make life easier.

Disruptive strategies are essential to grow the pharma industry.

One of the most special things about Pharmaceutical Executive®, in my opinion, is when people share their stories—where they came from; how their upbringing or education or background impacted their desire to work in pharma; any personal ties to their work, such as finding new treatments in a specific disease state due to a loved one having been impacted by that same disease; and just generally sharing their passion for their work. As someone who’s worked in pharma journalism for many years, there’s something extraordinary to hear about the why for individuals.